Panoramic Capital LLC Purchases Shares of 54,821 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Panoramic Capital LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 54,821 shares of the biopharmaceutical company's stock, valued at approximately $2,621,000. Halozyme Therapeutics makes up 1.4% of Panoramic Capital LLC's portfolio, making the stock its 20th biggest holding.

Several other institutional investors also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Halozyme Therapeutics by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,087 shares of the biopharmaceutical company's stock valued at $4,117,000 after acquiring an additional 3,874 shares during the last quarter. Janus Henderson Group PLC increased its position in Halozyme Therapeutics by 28.8% in the fourth quarter. Janus Henderson Group PLC now owns 702,085 shares of the biopharmaceutical company's stock worth $33,566,000 after purchasing an additional 156,912 shares during the last quarter. Gotham Asset Management LLC increased its position in Halozyme Therapeutics by 9.7% during the fourth quarter. Gotham Asset Management LLC now owns 47,440 shares of the biopharmaceutical company's stock valued at $2,268,000 after acquiring an additional 4,178 shares during the last quarter. Clark Capital Management Group Inc. grew its holdings in shares of Halozyme Therapeutics by 30.4% in the fourth quarter. Clark Capital Management Group Inc. now owns 178,827 shares of the biopharmaceutical company's stock worth $8,550,000 after purchasing an additional 41,655 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on HALO. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $73.00 to $62.00 in a research report on Wednesday. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Stock Performance

Shares of HALO traded up $3.07 during mid-day trading on Friday, hitting $52.02. The stock had a trading volume of 3,976,155 shares, compared to its average volume of 1,601,947. The company has a market cap of $6.41 billion, a PE ratio of 15.17, a PEG ratio of 0.42 and a beta of 1.26. The company's fifty day simple moving average is $60.69 and its two-hundred day simple moving average is $55.90. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the previous year, the firm posted $0.79 EPS. The firm's quarterly revenue was up 35.2% on a year-over-year basis. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares of the company's stock, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,697 shares of company stock valued at $1,276,552. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.